{"id":194552,"name":"TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.)","slug":"tiber-creek-group-on-behalf-of-emd-serono-inc","state":"DC","country":"United States of America","description":"Biopharmaceuticals.","totalSpending":1200000,"filings":32,"yearlySpending":[{"year":2018,"income":60000},{"year":2019,"income":40000},{"year":2020,"income":40000},{"year":2021,"income":200000},{"year":2022,"income":260000},{"year":2023,"income":200000},{"year":2024,"income":200000},{"year":2025,"income":200000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["TIBER CREEK HEALTH STRATEGIES, INC."],"lobbyists":["JAMES HALL"],"govEntities":["SENATE"],"sampleDescriptions":["Issues related to pharmaceutical pricing. H.R. 1625, Vehicle for Consolidated Appropriations Act of 2018. Issues related to Medicare Part D.","Issues related to pharmaceutical pricing. Issues related to drug development.","Issues related to pharmaceutical pricing. Issues related to drug development.","Issues related to pharmaceutical pricing. Issues related to drug development.","Issues related to pharmaceutical pricing. Issues related to drug development."]}